Delaware
|
2834
|
82-4566526
|
Tony Jeffries
Miranda Biven
Jennifer Knapp
Wilson Sonsini Goodrich & Rosati
Professional Corporation
650 Page Mill Road
Palo Alto, CA 94304
(650) 493-9300
|
Mark Meltz
Chief Operating Officer and General Counsel
Kinnate Biopharma Inc.
11975 El Camino Real, Suite 101
San Diego, CA 92130
(858) 299-4699
|
Charles Kim
Jonie Kondracki
Dave Peinsipp
Cooley LLP
4401 Eastgate Mall
San Diego, CA 92121
(858) 550-6000
|
Large accelerated filer
|
☐
|
Accelerated filer
|
☐
|
Non-accelerated filer
|
☒
|
Smaller reporting company
|
☒
|
Emerging growth company
|
☒
|
Title of Each Class
of Securities to be Registered
|
Amount to be
Registered(1)
|
Proposed Maximum
Offering Price Per
Share
|
Proposed Maximum
Aggregate Offering
Price
|
Amount of
Registration Fee(2)
|
Common stock, $0.0001 par value per share
|
575,000
|
$20.00
|
$11,500,000.00
|
$1,255
|
(1) |
Represents only the additional number of shares being registered and includes 75,000 additional shares of common stock that the underwriters have the option to purchase. Does not
include the securities that the registrant previously registered on the registration statement on Form S-1 (File No. 333-250086).
|
(2) |
The registration fee is calculated in accordance with Rule 457(a) under the Securities Act of 1933, as amended, based on the proposed maximum aggregate offering price. The registrant
previously registered securities at an aggregate offering price not to exceed $251,275,000 on a registration statement on Form S-1 (File No. 333-250086), which was declared effective by the Securities and Exchange Commission on December 2,
2020. In accordance with Rule 462(b) under the Securities Act of 1933, as amended, an additional amount of securities having a proposed maximum aggregate offering price of $20.00 is hereby registered, which includes shares issuable upon the
exercise of the underwriters’ option to purchase additional shares.
|
Exhibit
Number
|
Description
|
|
KINNATE BIOPHARMA INC.
|
||
By:
|
/s/ Nima Farzan
|
|
Nima Farzan
|
||
President and Chief Executive Officer
|
Signature
|
Title
|
Date
|
||||
/s/ Nima Farzan
|
President, Chief Executive Officer and Director (Principal Executive Officer)
|
December 2, 2020
|
||||
Nima Farzan
|
||||||
/s/ Mark Meltz
|
Chief Operating Officer and General Counsel (Principal Financial and Accounting Officer)
|
December 2, 2020
|
||||
Mark Meltz
|
||||||
*
|
Chair of the Board
|
December 2, 2020
|
||||
Dean Mitchell
|
||||||
*
|
Director
|
December 2, 2020
|
||||
Melissa Epperly
|
||||||
*
|
Director
|
December 2, 2020
|
||||
Keith Flaherty, M.D.
|
||||||
*
|
Director
|
December 2, 2020
|
||||
Carl Gordon, Ph.D.
|
||||||
*
|
Director
|
December 2, 2020
|
||||
Stephen Kaldor, Ph.D.
|
||||||
*
|
Director
|
December 2, 2020
|
||||
Michael Rome, Ph.D.
|
||||||
*
|
Director
|
December 2, 2020
|
||||
Laurie Smaldone Alsup
|
||||||
*
|
Director
|
December 2, 2020
|
||||
Jim Tananbaum, M.D.
|
||||||
*By: /s/ Nima Farzan
|
||||||
Nima Farzan, Attorney-in-fact
|
Wilson Sonsini Goodrich & Rosati
Professional Corporation
650 Page Mill Road
Palo Alto, California 94304-1050
o: 650.493.9300
f: 650.493.6811
|
Very truly yours,
|
|
/s/ Wilson Sonsini Goodrich & Rosati
|
|
WILSON SONSINI GOODRICH & ROSATI
|
|
Professional Corporation
|